Nivo-lution in mesothelioma

Aaron Mansfield, Marjorie G. Zauderer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.

Original languageEnglish (US)
Pages (from-to)5438-5440
Number of pages3
JournalClinical Cancer Research
Volume25
Issue number18
DOIs
StatePublished - Sep 15 2019

Fingerprint

Mesothelioma
Japan
Phase II Clinical Trials
Therapeutics
nivolumab
Malignant Mesothelioma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Nivo-lution in mesothelioma. / Mansfield, Aaron; Zauderer, Marjorie G.

In: Clinical Cancer Research, Vol. 25, No. 18, 15.09.2019, p. 5438-5440.

Research output: Contribution to journalArticle

Mansfield, Aaron ; Zauderer, Marjorie G. / Nivo-lution in mesothelioma. In: Clinical Cancer Research. 2019 ; Vol. 25, No. 18. pp. 5438-5440.
@article{61cd0eb3013c406d9fa79e35ba016358,
title = "Nivo-lution in mesothelioma",
abstract = "The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.",
author = "Aaron Mansfield and Zauderer, {Marjorie G.}",
year = "2019",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-19-1836",
language = "English (US)",
volume = "25",
pages = "5438--5440",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Nivo-lution in mesothelioma

AU - Mansfield, Aaron

AU - Zauderer, Marjorie G.

PY - 2019/9/15

Y1 - 2019/9/15

N2 - The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.

AB - The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.

UR - http://www.scopus.com/inward/record.url?scp=85072234485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072234485&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-19-1836

DO - 10.1158/1078-0432.CCR-19-1836

M3 - Article

C2 - 31315884

AN - SCOPUS:85072234485

VL - 25

SP - 5438

EP - 5440

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -